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Abstract
Avicins, a class of electrophilic triterpenoids with pro-apoptotic, anti-inflammatory and antioxidant properties, have been
shown to induce redox-dependant post-translational modification of cysteine residues to regulate protein function. Based
on (a) the cross-talk that occurs between redox and phosphorylation processes, and (b) the role of Stat3 in the process of
apoptosis and carcinogenesis, we chose to study the effects of avicins on the processes of phosphorylation/
dephosphorylation in Stat3. Avicins dephosphorylate Stat3 in a variety of human tumor cell lines, leading to a decrease
in the transcriptional activity of Stat3. The expression of Stat3-regulated proteins such as c-myc, cyclin D1, Bcl2, survivin and
VEGF were reduced in response to avicin treatment. Underlying avicin-induced dephosphorylation of Stat3 was
dephosphorylation of JAKs, as well as activation of protein phosphatase-1. Downregulation of both Stat3 activity and
expression of Stat 3-controlled pro-survival proteins, contributes to the induction of apoptosis in avicin treated tumor cells.
Based on the role of Stat3 in inflammation and wounding, and the in vivo inhibition of VEGF by avicins in a mouse skin
carcinogenesis model, it is likely that avicin-induced inhibition of Stat3 activity results in the suppression of the pro-
inflammatory and pro-oxidant stromal environment of tumors. Activation of PP-1, which also acts as a cellular economizer,
combined with the redox regulation by avicins, can aid in redirecting metabolism from growth promoting anabolic to
energy sparing pathways.
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Introduction
Coincident with the identification of the human genome, as well
as increased understanding of gene networks, a quiet renaissance is
occurring in the development of natural products as drug
candidates [1]. Although almost one-half of all current medica-
tions are plant products or their derivatives, the often superior
specificity and potency of these small molecules (,2500 Da)
compared to synthetic molecules is not widely appreciated. Their
size, three dimensional structure, as well as functionality often
make natural products outstanding drug candidates or pharma-
cophores for novel and imaginative new drugs [2]. The interest in
natural products parallels the important advances in natural
product chemistry, bioengineering, and biocatalysis [3].
Avicins,afamilyofdesertplant-derived triterpenesthathavebeen
identified, purified and characterized by our group, offers interesting
possibilities for treating complex diseases of ageing, where targeting
single proteins may not offer optimal results. The extraction and
purification of avicins from the ground pods of Acacia victoriae have
beendescribedindetailbyJayatilakeetal[4].Usinginductionofcell
cytotoxicity as a screen, two fractions namely avicin D and avicin G
were identified as most active [4–6]. The HPLC profile of the
material used and the chemical strucures of the two avicins have
been shown in Supplemental information (Figure S1). The avicin D
obtained as a white amorphous powder is about 96% pure and has a
molecular weight of 2,104 atomic mass units [4]. Further details
regarding the chemistry of the avicin molecules have been described
earlier by [4]. Based on the higher recovery of avicin D fraction, we
chose to use itfor all subsequent studies. Avicin D has been shown to
inhibit NF-kB [7] and activate NF-E2-related factor 2 (Nrf2) [8]
respectively, both in a redox-dependant manner, accounting for its
anti-inflammatory [7,9] and antioxidant properties [8]. The ability
of avicins to interact with, and modify cysteine residues was first
demonstrated in a bacterial system with OxyR as a target, wherein
we demonstrated that the distal portion of the avicin side chain
formed a reversible and covalent thioester bond with the critical
cysteine(SH)ontheOxyRmolecule[10].Thisproteinmodification,
termed avicinylation, suggested to us that avicins can induce post-
translational changes in proteins to regulate their function.
Post-translational modifications of proteins are important ways
by which small molecules modulate human physiology [11]. Often
different post-translational modifications occur in tandem, and the
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outcome. One such protein modification that often accompanies
thiol modifications is the phosphorylation/dephosphorylation of
proteins. We have demonstrated that avicins inhibit oxygen
consumption and ATP generation in healthy as well as tumor cells
[12–14]. Decrease in the generation of cellular ATP has an
inhibitory effect on protein-phosphorylation [15], thereby signif-
icantly affecting various signaling pathways [16]. In order to study
the role of avicins in regulating the phosphorylation and thereby
function of proteins, we chose to study the effects of avicin D on
Stat 3 signaling. Stat3, a regulator of cell survival, wounding and
metabolism is constitutively activated by phosphorylation in most
cancers [17,18]. Targeting the Stat signaling pathway could
provide an important mode of anti-cancer therapy [17], based on
role of Stat proteins in regulation of cell proliferation, differenti-
ation, survival, malignant transformation and oncogenesis [18].
Results
Avicin D inhibits constitutive and induced Stat3
phosphorylation in multiple myeloma cells
One of the critical steps leading to the activation of Stat3 is its
phosphorylation at Tyr 705 and/or Ser727. Treatment of U266
cells with avicin D (1 mM), resulted in a time-dependant decrease
in Stat3 phosphorylation, both at Tyr 705 and Ser 727, with no
significant changes in the levels of total Stat3 (Fig. 1A). A 20%
reduction in levels of phospho-Stat3 (Ser 727 and Tyr 705) was
observed within 1 hr of treatment, and at the end of 24 hr only
about 15–35% of the phospho- Stat3 was detectable (Fig. 1B).
We next evaluated the optimal dose of avicin D required for
dephosphorylation of both constitutive and IL-6 induced Stat3 in
U266 cells. As shown in Fig. 1C 0.5–1.0 mM of avicin D (16 hr)
was required to dephosphorylate Stat3 at Ser 727, while lower
doses had no effect. Dephosphorylation of IL-6 induced phospho-
Stat3 (Tyr 705) also required at least 0.5 mM of avicin D (Fig 2D).
In all the above studies, no significant changes were observed in
the levels of total Stat3. Based on these results, for the rest of the
study, we chose to treat cells with 1 mM of avicin D for 16 hr.
To demonstrate that the avicin-mediated regulation of Stat3
was not restricted to U266 cells, we studied some other multiple
myeloma cell lines. These cells have been found to be sensitive to
avicin-induced killing [19]. A time dependant decrease in the
constitutive levels of phospho-Stat3 (Ser 727 and Tyr 705) was
observed in RPMI-8226 and SKO-007 cells (Fig. 2A&B). In MM1
cells, IL-6 induced phosphorylation of Stat3 was inhibited in
response to avicin D in a time dependant manner (Fig. 2C).
Avicin D inhibits the nuclear localization of Stat3 in
myeloma cells
In the absence of cytokine stimulation, Stats exist as stable, non-
phosphorylated dimers, which constantly shuttle between the
cytoplasm and nucleus [20]. However, the phosphorylated Stat
protein is retained in the nucleus and is only released upon
dephosphorylation by nuclear phosphatases. Therefore, besides
nuclear translocation, nuclear retention of phosphorylated Stat is
also crucial for its activation. We studied the effect of avicin D on
the localization of both constitutive and IL-6 induced Stat3 in
U266 (Fig. 3A) and RPMI-8226 (Fig. 3B) cells. Consistent with
avicin-induced dephosphorylation of Stat3, is the observation that
following avicin D treatment, both untreated and IL-6 treated cells
show reduced presence of Stat3 in the nucleus. This could be due
inhibition in the nuclear translocation and/or nuclear retention of
Figure 1. Avicin D dephosphorylates Stat3 both in a time and dose-dependant manner. (A) U266 cells were treated with 1 mM of avicin D
for 0–24 hrs. Whole cell lysates were analyzed for phospho-Stat3 (Ser 727 and Tyr 705) and total Stat3 expression by Western blot analysis as
described in the methods. (B) Quantitation of the total and phospho-Stat3 bands from Fig. 1A. (C) U266 cells were treated with 0–1 mM of avicin D for
16 hrs. Whole cells lysates were analyzed for phospho-Stat3 (Ser 727) levels. (D) U266 cells pre-treated with 0–1 mM of avicin D (16 h) were then
exposed to IL-6 (10 ng/ml) for 30 min. Whole cell lysates were analyzed for phospho-Stat3 (Tyr 705) levels by western blot analysis.
doi:10.1371/journal.pone.0005578.g001
Avicin-D Inactivates Stat3
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ylating Stat3 and inhibiting its nuclear localization, could affect the
transcriptional activity of Stat3.
Avicin D inhibits Stat3-dependant gene expression
Phosphorylated Stat3 in the nucleus binds to DNA and
regulates the transcription of several target genes. U266 cells
transiently transfected with Ly6E Stat3-luciferase construct were
treated with avicin D. Constitutive, and IL-6 induced Stat3
activity was assessed by measuring the luciferase activity. Pre-
treatment of cells with avicin D resulted in a significant decrease in
both the constitutive as well as IL-6 induced Stat3-luciferase
activity (Fig. 4A), suggesting a decrease in the transcriptional
potential of Stat3.
IL-6, a major activator of Stat3, particularly in myeloma cells, is
known to be under the transcriptional regulation of Stat3 itself,
thereby constituting a feedback loop [21,22]. To study the effect of
avicin D on Stat3-induced IL-6 production, we assayed the cell
culture medium for IL-6 levels. U266 cells treated for 48 hrs with
avicin D, showed a dose dependant decrease in IL-6 production
(Fig. 4B), which is consistent with the avicin-induced inhibition of
Stat3 phosphorylation and transcriptional activity.
To further demonstrate the reduced transcriptional activity of
Stat3 in avicin-treated cells, we studied the expression of Stat3
regulated proteins such as cyclin D1, c-myc, survivin, Bcl-2, Mcl-1,
and VEGF. As shown in Fig. 4C, U266 cells treated with avicin D
showed a time-dependant decrease in levels of these proteins.
While levels of cyclin-D, Mcl-1 and VEGF began to decline within
2–4 hrs of avicin D treatment, Bcl2 and survivin levels decreased
following longer (8–16 hrs) treatments. These findings are in
confirmation with an earlier study, showing that avicin D
selectively induces apoptosis and down regulates pro-apoptotic
proteins in cutaneous T-cell lymphoma cells [23].
Role of kinases in avicin D-induced dephosphorylation of
Stat3
Based on the observations so far, we were interested in
understanding the mechanism(s) underlying avicin D-induced
dephosphorylation of Stat3. Dephosphorylation of a protein can
be a result of either inactivation of specific kinases or activation of
phosphatases. Janus kinases (JAKs) upon phosphorylation are
known to activate Stat3 in response to various stimuli such as
cytokines, and growth factors [24,25]. Treatment of U266 cells
with avicin D for 0–24 h resulted in dephosphorylation of both
Figure 2. Avicin D dephosphorylates both constitutive and induced Stat3 in myeloma cell lines. (A) RPMI-8226, (B) SKO-007 and (C) MM1
cells were treated with 1 mM of avicin D for 0–24 hrs. At the end of the avicin D treatment, MM1 cells were additionally exposed to IL-6 (10 ng/ml,
30 min). Whole cell lysates were analyzed for phospho-Stat3 (Ser 727 and Tyr 705) and total Stat3 expression by Western blot analysis as described in
the methods.
doi:10.1371/journal.pone.0005578.g002
Avicin-D Inactivates Stat3
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at Tyr 705 (Fig. 5A). No change in total JAK levels was observed.
Of the different members of the JAK family, JAK2 is known to be
involved in the tyrosine phosphorylation of Stat3 [26]. Based on
the finding that avicin D inhibits JAK2, we next wanted to see how
avicin D compares with known inhibitors of JAK2. For this
purpose, we used tyrphostin (AG490) and hexabromocyclohexane
(HBCH). While HBCH is a specific inhibitor of JAK2 [27],
AG490 targets both JAK2 and JAK3 [28]. Almost total
dephosphorylation of Stat3 was achieved with 1 mM of avicin D,
whereas much higher doses of AG490 (50–100 mM) (Fig 5B) and
HCBH (more than 25 mM) (Fig. 5C) were required for a
comparable effect. At the concentrations studied, avicin D in
combination with either of the inhibitors was as effective as by
itself in dephosphorylating Stat3 (Figs 5B & C). These findings
demonstrate the better potency of avicin D compared to some of
the known JAK2 inhibitors.
Role of phosphatases in avicin D-induced
dephosphorylation of Stat3
While the tyrosine phosphorylation of Stat3 and the kinases
involved have been extensively studied, very little is known about
the mechanisms underlying serine phosphorylation of Stat3. Some
of the kinases which have been suggested to play a role in serine
phosphorylation of Stat3 (MAPK, PI3K, PKCd and JNK) are all
either activated in response to avicin D, or are inhibited at a much
later time point. In the absence of any clear indications that avicins
inactivate a serine kinase to dephosphorylate Stat3, we decided to
evaluate the involved phosphatases. We first studied the effect of
phosphatase inhibitors on avicin-induced dephosphorylation of
Stat3 in U266 cells. Okadaic acid (OA), an inhibitor of PP1/PP2A
completely reversed the avicin-induced dephosphorylation, where-
as fostriecin, a PP2A/PP4 inhibitor had no effect at all (Fig. 6A),
suggesting the probable involvement of PP1. We next measured
the phosphatase activity in avicin D-treated U266 cells using P
32
labeled myelin basic protein as a substrate. As shown in Fig. 6B, a
5 fold increase in PP1 activity was observed following a 4 h
treatment with avicin D. To further confirm the role of PP1 in
avicin-induced Stat3 dephosphorylation, we used inhibitor-2 (I-2)
a specific PP1 inhibitor. In an in vitro assay, I-2 totally inhibited the
phosphatase activity in the lysates of avicin D-treated U266 cells
(Fig. 6C). Pretreatment of U266 cells with I-2 for 20 h,
significantly blocked avicin-mediated dephosphorylation of Stat3
(Fig. 6D), strongly suggesting the involvement of PP1. All these
results clearly point to the role of PP1 in avicin-mediated serine
dephosphorylation of Stat3.
Down regulation of Stat3 is involved in avicin-induced
cell death
Avicin D has been shown to induce cell death in a variety of
human tumor cells [6], including multiple myelomas [19]. The
findings reported here, suggest that targeting the Stat3 pathway
Figure 3. Cellular localization of Stat3 in avicin D-treated myeloma cells. U266 (A) and RPMI-8226 (B) cells pre-treated with 1 mM of avicin D
for 16 hrs were exposed to IL-6 (10 ng/ml) for 30 min. Staining and immunohistochemistry of Stat3 was done as described in the methods.
doi:10.1371/journal.pone.0005578.g003
Avicin-D Inactivates Stat3
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death. To investigate this, we first evaluated the sensitivity of U266
cells to avicin-induced cell death. Avicin D treated U266 cells
showed a dose and time-dependant inhibition of viability (Fig. 7A).
Any inference by avicin D in the assay due to its interaction with
MTT was ruled out as described in the methods.
Figure 4. Avicin D downregulates Stat3-induced protein expression. (A) Effect of avicin D on Stat3 -mediated luciferase gene expression.
U266 cells were transfected with Ly6E-Luciferase-Stat3 plasmid as described in the methods. 24 hrs later cells were washed and treated first with
avicin D (1 mM) for 16 hrs, and then exposed to IL-6 (10 ng/ml) for 30 min. Luciferase activity was measured as described in the methods. The
luciferase activity of the treated samples is expressed relative to the activity of untreated control (no avicin, no IL-6), which is taken as 100%. (B) Effect
of avicin D on IL-6 production in U266 cells. Cells were treated with 0–1 mM of avicin D for 48 hrs. Cell supernatants were assayed for IL-6 levels using
an ELISA kit. (C) Effect of avicin D on the expression of Stat3 regulated proteins. U266 cells were treated with 1 mM of avicin D for 0–24 hrs. Whole cell
lysates were analyzed for the expression of different proteins by western blot analysis as described in the methods.
doi:10.1371/journal.pone.0005578.g004
Avicin-D Inactivates Stat3
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treated with avicin D for 0–72 hrs were analyzed for annexin V-
FITC binding. Cells were simultaneously stained with propidium
iodide to check for their viability. Shown in Figure 7B, is a time
dependant increase in annexin V positive cells, indicative of
apoptosis. To further confirm the induction of apoptosis we
assayed avicin D-treated U266 cell lysates for cleavage of PARP, a
hallmark of apoptosis. Avicin D induced cleavage of PARP was
clearly detectable at 12 hr of treatment (Fig 7C), which is
consistent with the annexin V data.
After establishing that avicin D induces apoptosis in U266 cells,
we next asked if the apoptosis was related to the dephosphorylation
of Stat3. To address this question,we studied the effect of OA and I-
2,PP1inhibitorswhichhavebeenearliershownto reverse avicinD-
induced dephosphorylation of Stat3, on the induction of cell death.
As shown in Fig. 7D, U266 cells pre-treated with OA and I-2,
showed a partial inhibition of avicin D-induced cell death. The IC
50(concentration requiredtoinduce50%cellkill)valueforavicin D
alone was 1.4 mM, while in the presence of OA and I-2, this value
rose to 5.75 and 10.4 mM respectively. These findings clearly
indicate that inhibition of Stat3 does play a role in the mediation of
cell death following avicin treatment. The lack of complete
inhibition of avicin D-induced cell death in this experiment can
be explained by the fact that (a) only a part of the Stat3
dephosphorylation (at Ser 727) was reversed and (b) there are other
pathways shown to be involved in avicin-induced cell death [5–
7,29], which are not targeted by OA and I-2.
Avicin D induces dephosphorylation of Stat3 in a wide
variety of human tumors
Since Stat3 is constitutively activated in various human tumors
besides myelomas, we questioned if avicin D would regulate the
Stat3 activityinthesetumorstoo.Weselected threehumancell lines
of different origins that have been found to be sensitive to avicin-
induced killing. Shown in Fig. 8 is the dephosphorylation of Stat3 in
A431 (epidermoid), OVCAR3 (ovarian) and HepG2 (hepatocarci-
noma) cells treated with avicin D. These results indicate that avicins
target the Stat3 pathway in a wide variety of human tumors.
Figure 5. Effect of avicin D on Janus kinases in U266 cells. (A) U266 cells were treated with avicin D (1 mM) for 0–24 h. Whole cell lysates were
assayed for expression of phospho-JAK1, phospho-JAK2 and total JAK, using western blot analysis. These results were analyzed against changes in
the levels of phospho-Stat3 (Tyr 705). (B) Effect of AG490 on avicin D-induced dephosphorylation of Stat3 (Tyr 705). U266 cells were pretreated with
AG490 (0–100 mM) for 2 hrs, followed by a 16 hrs exposure to avicin D (1 mM). Cells treated with AG490 alone, were treated for 18 h with the
inhibitor. Whole cell lysates were assayed for expression of phospho-Stat3 and total Stat3 using western blot analysis. (C) Effect of HCBH on avicin D-
induced dephosphorylation of Stat3 (Tyr 705). U266 cells were pretreated with HCBH (0–25 mM) for 2 hrs, followed by a 16 hrs exposure to avicin D
(1 mM). Cells treated with HCBH alone, were treated for 18 h with the inhibitor. Whole cell lysates were assayed for expression of phospho-Stat3 and
total Stat3 using western blot analysis.
doi:10.1371/journal.pone.0005578.g005
Avicin-D Inactivates Stat3
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skin
To extrapolate the above-described effects of avicins to an in vivo
system, we used a mouse skin carcinogenesis model. Based on
recent reports [30] suggesting the role of Stat3 in the expression of
VEGF and tumor angiogenesis, we evaluated the levels of VEGF
in the skin sections of mice treated with DMBA. SENCAR mice
skin was treated with either acetone (control) or avicin D as
described in the methods, prior to treatment with DMBA.
The mean weights of the animals in all treatment groups were
analyzed by one-way ANNOVA. There were no significant
differences in body weight, body weight gains or food consumption
between animals treated with acetone or avicins, suggesting no
dramatic changes in the performance of treated animals. Tumor
progression was monitored by measuring epidermal hyperplasia
and total dermal cellularity as described earlier [9]. The
histological evaluation of tumor progression and effect of avicins
on it have also been described previously [9].
Immunohistochemistry studies revealed that avicin treated skin
showed a dramatic decrease in the levels of VEGF, as compared to
the acetone treated (control) skin (Fig. 9A). To ensure that the
decreased levels of VEGF translated into decrease in angiogenesis,
we next studied the levels of CD31, an endothelial cell marker that
is indicative of the microvascular networks within the cells. As
shown in Fig. 9B, avicin treatment induced a decrease in the
CD31 levels, as compared to the control demonstrating the anti-
angiogenic potential of avicins.
Discussion
Post-translational protein modification is emerging as an
important regulatory control over cellular function [11]. Here
we demonstrate avicin D-induced dephosphorylation of Stat3, and
down regulation of Stat3-dependant proteins. Stat3, persistently
activated in several types of human cancers has been now shown
to play a critical role in the process of carcinogenesis [31–33] by
enhancing tumor cell proliferation, survival as well as cellular
transformation [33,34]. Based on its involvement in the process
and maintenance of oncogenesis, activity of Stat3 as a transcrip-
tional activator is a prime target for anticancer interventions.
Figure 6. Avicins activate a ser/Thr phosphatase. (A) Effect of phosphatase inhibitors on avicin D-induced dephosphorylation of Stat3. Cells
were treated with okadaic acid (1 mM) or fostriecin (1 mM) for 1 hr prior to a 4 hr treatment with avicin D (1 mM). Whole cell lysates were analyzed for
phospho-Stat3 (ser 727) and total Stat3 expression by Western blot analysis as described in the methods. (B) Avicin D enhances PP1 activity in U266
cells. Cells were treated with 1 mM of avicin D for 0–4 hrs. PP1 was immunoprecipitated and its activity was assayed as described in the methods. (C)
Avicin D-induced PP1 activity is blocked by I-2. PP1 was immunoprecipated from avicin D treated (1 mM, 4 hrs) U266 cell lysates. 200 nM of I-2 was
added into the reaction mix and phosphatase activity was measured as described in the methods. (D) Avicin D-induced Stat3 dephosphorylation is
reversed by I-2. U266 cells were treated with 100- and 200 nM of I-2 for 20 hrs prior to a 4 hr treatment with avicin D (1 mM). Whole cell lysates were
analyzed for phospho-Stat3 (ser 727) and total Stat3 expression by Western blot analysis as described in the methods.
doi:10.1371/journal.pone.0005578.g006
Avicin-D Inactivates Stat3
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induce more than one form of posttranslational modification in
different proteins [10,35], which in turn translates into some of its
key properties. Avicins were first characterized as molecules that
specifically induce apoptosis by direct perturbation of the
mitochondria [5], in a wide variety of human tumors. NF-kB
and Nrf2, both transcription factors containing cysteine residues
critical for their activity, are regulated by avicins in a redox
sensitive manner [7,8], probably accounting for avicins’ anti-
inflammatory and cytoprotective properties. Avicins have also
been shown to reduce oxygen consumption and levels of cellular
ATP [13,14], which can lead to a hypo metabolic state [12–14].
The lowering of cellular ATP levels could contribute to avicins’
ability to dephosphorylate proteins and thereby regulate their
function [6]. In the present study we focused on the effects of
avicins on Stat3 phosphorylation. Avicin D treatment resulted in
dephosphorylation of both constitutive and induced Stat3 in a time
and dose-dependant manner, leading to a decrease in the
transcriptional activity of Stat3. Cultures of avicin treated
myeloma cells showed a decrease in the levels of IL-6, a major
inducer of Stat3 activity, which is also known to be under the
transcriptional regulation of Stat3 [21,22]. This decrease in IL-6
levels could also contribute to the decrease in Stat3 activation, in
avicin treated cells. In addition to IL-6, the expression of cyclin
D1, c-myc, survivin, Bcl2, Mcl1, and VEGF, all of which are
regulated by Stat3 activity, and play a crucial role in apoptosis and
progression of cancer [33], are also down regulated in response to
avicin D.
Tyrosine phosphorylation of Stats has been extensively studied,
and the role of JAKs is well accepted [24–26]. Dephosphorylation
of JAK2 appears to be a mechanism for avicin D-induced
dehosphorylation of Stat3 at Tyr 705, though the involvement of
other members of the JAK family such as JAK1 or JAK3 cannot
be ruled out. Serine phosphorylation of Stats is much less
understood, and the involved kinases are not clearly known.
Recent reports suggest the involvement of PI3K, PKC d, ERK,
JNK and mTOR in serine phosphorylation of Stat3 [26–40].
Avicins have been shown to inhibit PI3K [6], mTOR [29], and
PKC d (unpublished data), though long (12–16 hrs of avicin
treatment) after Stat3 dephosphorylation is observed. ERK and
Figure 7. Avicin D induced dephosphorylation and apoptosis are related. (A) The growth inhibitory activity avicin D was measured by the
MTT assay. Cells (1610
4/well) were cultured with 0–10 mM of avicin D in 96-well plates for 0–72 h at 37uC. MTT assay was performed as described in
the methods. (B) Annexin V-FITC binding in avicin D-treated U266 cells. U266 cells (1610
6/ml) were treated with 1 mM of avicin D for 0–72 hrs. Cells
were stained and analyzed by flow cytometry as described in the methods. (C) Cleavage of PARP by avicin D. U266 cells (1610
6) were treated with
1 mM of avicin D for 0–72 hrs. Whole cell lysates were prepared and assayed for expression of cleaved PARP, using western blot analysis as described
in the methods. (D) Effect of OA and I-2 on avicin-induced cell death. In a 96-well plate U266 cells (1610
4/well) were pretreated with OA (100 nM) and
I-2 (100 nM) for 12 hr. Next the avicin D (0–10 mM) was added to the culture and incubated for 24 h at 37uC. MTT assay was performed as described
in the methods.
doi:10.1371/journal.pone.0005578.g007
Avicin-D Inactivates Stat3
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(unpublished results). There are some studies suggesting that
activation of MEKs and ERKs can antagonize, and thereby
inhibit IL-6 induced JAK-Stat signaling [41]. However, PD98059,
an inhibitor of MEK1/2, had no significant effects on avicin-
induced dephosphorylation of Stat3 (Ser 727) (data not shown),
thereby ruling out the possible involvement of ERK activation in
avicin-induced Stat3 (Ser 727) dephosphorylation. In the absence
of any clear indications that avicins inactivate a serine kinase, we
next asked whether any ser/Thr phosphatase activity was
enhanced. . Majority of the known serine/threonine phosphatases
belong to the PP1 and PP2A families. The net hydrolysis of
phosphoserine (pS) and phosphotyrosine (pT) versus phosphotyr-
osine (pY) residues is believed to be mediated via distinct yet
related mechanisms [10]. One study using phosphatase inhibitors
have implicated the role of PP2A in the dephosphorylation of
Stat3 [42]. While fostriecin a PP2A/PP4 inhibitor had no effect on
avicin-induced dephosphorylation of Stat3, OA and inhibitor-2 (I-
2), both PP1 inhibitors, completely reversed avicin D-induced
dephosphorylation of Stat 3 (Ser 727), suggesting the probable
involvement of PP1. Using an in vitro serine/threonine phosphatase
assay system, we found that avicin D induces PP1 activity. Taken
together, these results suggest a role for PP1 in Stat3 dephosphor-
ylation by avicins, though an additional involvement of PP2A
cannot be completely ruled out.
The activation of a phosphatase that can deactivate phosphor-
ylation (serine) of an important oncogenic signaling molecule,
reported in this paper is a novel finding. How exactly the avicin
molecule activates PP1 is not clear. The ability of the avicin
molecule to bind to SH groups could regulate the activation of Fe
and/or Zn in the bimetallic center. Alternatively, avicins might
inhibit the endogeneous inhibitors of PP1 (DARPP32, I-1 and I-2),
which also appear to affect the B12–B13 loop [43].
Stat3 as mentioned earlier is activated in several human tumors,
rendering them resistant to apoptotsis by regulating various anti-
apoptotic proteins [31]. Avicin D-induced dephosphorylation of
Stat3 and the subsequent inhibition of its transcriptional activity,
contributes to sensitizing the cells to apoptosis. This was shown in
U266 cells, which undergo apoptotsis in response to avicin
treatment. Upon inhibition of Stat3 dephosphorylation (Ser 727)
by using PP1 inhibitors, avicin D-induced cell death was inhibited.
Hence targeting Stat3 could be another mechanism by which
avicins induce cell death. The ability of avicins to target
degenerate pathways leading to cell death, in a systems manner
is likely to make it more effective in a variety of tumor cells which
might be mutated for one or the other pathways.
Studies from DiGiovanni’s laboratory have shown the involve-
ment of Stat3 in both the initiation and promotion of epithelial
carcinogenesis [44]. One of the key requirements for successful
tumorigenesis is the establishment of neovascularization or
angiogenesis, in order to acquire nutrients for continued growth
and metastatic spread [45]. VEGF, a key inducer of angiogenesis
[46], is believed to be regulated mainly by two transcription
activators, namely hypoxia inducible factor-1 (HIF-1) and Stat3
[47]. Recent studies have shown that Stat3 regulates the basal as
well as growth signal-induced expression of HIF-1 [47], which like
Figure 8. Avicin D dephosphorylates Stat3 in a variety of human tumor cell lines. Cells were treated with 1 mM of avicin D for 0–24 hrs.
Whole cell lysates were analyzed for phospho-Stat3 and total Stat3 by Western blot analysis as described in the methods.
doi:10.1371/journal.pone.0005578.g008
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mediates PI3K/Akt-induced VEGF expression [48]. Unpublished
results from our laboratory also show avicins down regulate HIF-1
levels in human tumor cells. Skin sections from avicin-treated mice
showed dramatic decrease in the levels of VEGF accompanied by
a decrease in CD31 staining, which is indicative of a reduction in
angiogenesis. Avicins therefore can inhibit VEGF expression by
down regulating both the Stat3 as well as HIF-1 activity.
One of the underlying causes of carcinogenesis is believed to be
sustained cellular stress, and chronic cellular injury leading to
wounds that fail to heal causing unabated inflammation [49,50].
Thus, chronic exposure to UV light, chemical carcinogens
contained in tobacco products, as well as environmental toxins
and saturated fats, often result in tissue injury, inflammation,
insufficient repair, exposure to oxygen and nitrogen radicals and
eventually in the selection of mutations and genomic instability.
Tumors characterized by inflammatory or wounding phenotype,
have been found to respond poorly to treatment, as compared to
tumors that do not show this phenotype [50]. Stat3 forms a nodal
point of an assembly of proteins that regulate wounding, chronic
injury, inflammation, and tumor cell survival [51]. Recent studies
have implicated the role of Stat3 in inducing a subset of pro-
inflammatory IL-17-producing helper T cells (THi) [52] Consti-
tutive activation of Stat3 has been found in intestinal T cells from
Crohn’s disease patients [53]. Constitutive activation of Stat3 is
also observed in various tumors and is correlated with poor
prognosis [54–58]. Considering the pivotal role Stat3 plays in
these processes, the ability of avicins to suppress Stat3 signaling
and transcriptional activity supports the idea of avicin, or an
analog, as a candidate drug for malignancy. This idea is further
supported by the exquisite in vitro sensitivity of multiple myeloma
cells, which express high levels of constitutively activated Stat3, to
avicins [19].
Many signals and signaling systems are shared between plants
and mammals [59]. So it now should be no surprise to discover a
plant molecule to which human cells can sense and respond to. For
example, other plant compounds such as epigallocatechin-3-
gallate (EGCG) and curcumin have also been shown to regulate
phosphorylation and activity of Stat3 in human cells [60,61]. A
new field of chemical biology, which studies the metabolome of
lower organisms and how these small molecules perturb human
biological targets, is emerging [16]. These so-called secondary
metabolites, which are used by plants as defensive molecules,
clearly can influence many biological functions in human cells
such as immunity, behavior, reproduction, and growth and are
serving as new leads for pharmaceuticals.
The emerging recognition of the intersection of metabolic stress,
inflammation, wounding with diseases of aging such as cancer has
stimulated a search for compounds that can re-establish metabolic
homeostasis. Stat3 sits at the nexus point in signaling pathways
and transcription in these processes. The ability of avicins, a
natural product shaped by a million years of evolutionary
selection, to regulate post-translational protein changes, in
particular redox and phosphorylation/dephosphorylation, offers
new insights in the potential treatment of metabolic stress. Protein-
reactive natural products, in particular electrophiles, have become
an important focal point for the discovery of new drug candidates
[62]. The ability to activate PP1, a cellular economizer [63],
together with the above mentioned effects of avicins on cellular
metabolism, suggest that further studies of the chemical biology of
Figure9.EffectofavicinDonlevels ofVEGFandCD31inmouseskin.Micetreatedwithacetone(control)oravicinwereexposedtoDMBAfor8
weeks. At the end of the treatment, skin sections were analyzed for (A) VEGF and (B) CD 31 levels as described in the methods (H&E Staining;6400).
doi:10.1371/journal.pone.0005578.g009
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Materials and Methods
Cell lines
All the cell lines used were of human origin. U266, RPMI-8226,
SKO-007 and MM1 (all multiple myelomas), A431 (epidermoid),
and OVCAR3 (ovarian), were maintained in RPMI 1640. HepG2
(hepatoblastoma) cells were grown in alpha-MEM. All the media
were supplemented with 10% FBS and 2 mM L-glutamine.
Reagents and kits
Avicins were extracted and purified from ground seed pods of
Acacia victoriae as described earlier [4]. Anti-Stat3, -phospho
Stat3 (Ser 727), -phospho Stat3 (Tyr 705), -cleaved PARP, -cyclin
D1, -c-myc, -Bcl-2 and -Bcl-xL antibodies were all purchased from
Cell Signaling Technology (Beverly, MA ). Anti- survivin, anti-
VEGF and anti-CD31 antibodies were obtained from Novus
Biologicals (Littleton, CO), Abcam Inc., (Cambridge, MA) and BD
Biosciences (San Jose, CA) respectively. Anti-PP-1 antibody was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). AG
490 and Hexabromocyclohexane (HBCH) were purchased from
Calbiochem (Gibbstown, NJ). Human interleukin-6 (IL-6) and hu
IL-6 ELISA kit were purchased from BD Pharmingen (San Jose,
CA) and R&D Systems (Minneapolis, MN) respectively. Annexin
V-PI kit was purchased from Beckman Coulter, Fullerton, CA.
The PP-1 assay kit and the luciferase assay kit were purchased
from New England Biolabs (Beverley, MA) and Promega
(Madison, WI) respectively. Ly6E-Luciferase-Stat3 plasmid was a
kind gift from Dr. Prahlad Ram (Dept. of Systems Biology, M.D.
Anderson Cancer Center, and Houston, TX, USA).
MTT Assay
The growth inhibitory activity of avicin D was measured by the
MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium
bromide] reduction assay as described earlier [5]. There have
been reports of interference by chemotherapeutic agents in the
MTT assay [64]. Any interaction between avicin D and MTT that
could interfere with the assay was ruled out by evaluating various
concentrations of avicin D incubated with medium alone (no cells)
by the MTT assay.
Annexin V-FITC Binding Assay
Induction of apoptosis was studied by annexin V-FITC binding
assay using a kit from Beckman Coulter. Treatment and staining
of cells was done as per the kit instructions. Briefly, U266 (1610
6)
were treated with 1 mM of avicin D for 0–72 hrs at 37uC. After
washing the cells in cold PBS, they were resuspended in binding
buffer. Annexin V-FITC conjugate was added (1 mg/ml) and
incubated for 15 min at room temperature in the dark. Cells were
then stained with propidium iodide (5 mg/ml) and analyzed by
flow cytometry [65].
Treatment of cells and Western blot analysis
Cells were serum starved prior to treatment with avicins. In case
of Stat3 induction by IL-6, cells were treated with 10 ng/ml of IL-
6 for 30 min. Whole cell lysates were prepared from untreated and
treated cells. Cellular proteins (50–100 mg) were resolved on an
SDS/10% polyacrylamide gel. Levels of different proteins were
analyzed by Western blot analysis using the respective antibodies.
Protein bands were detected by chemiluminescence (ECL,
Amersham Pharmacia) and quantitated using the Image J
software.
Immunofluorescent Staining
Serum starved U266 cells were either untreated or treated with
avicin D (1 mM) for 16 hrs. Cells were next exposed to IL-6
(10 ng/ml) for 30 min. After treatment, cells were washed twice
with PBS, and fixed with 4% paraformaldehyde. The cells were
permeabilized using 1% Triton X-100 and 0.5% NP40. After
blocking the cells with 1% BSA, they were incubated with primary
antibody (2 hrs) followed by secondary (Rhodamine) antibody
(1 hr). Cells were then stained with 49, 6-diamidino-2-phenylindole
(DAPI) to permit visualization of nuclear DNA. The immunoflu-
orescence was visualized by using a Leica DM LB fluorescence
microscope. Images were captured with an automatic imaging
system.
Transfection and Assay of Luciferase activity
U266 cells were transfected with Ly6E-luciferase construct
(4 mg) and b-galactosidase (b-gal) construct (2 mg) using the Amaxa
transfection system (Amaxa, Cologne, Germany). 24 hrs post
transfection, cells were washed and transferred into RPMI 1640
containing 1% FBS. Cells were then treated with avicin D for
16 hrs, followed by a 30 min exposure to IL-6 (10 ng/ml).
Luciferase activity was measured by using the luciferase assay kit
according to the manufacturer’s protocol. Data were normalized
for the b-gal activity, which was measured using the b-gal assay
system from Promega.
Assay for serine/threonine phosphatase activity
Serum starved U266 cells were treated with avicin D. Cells were
lysed in lysis buffer containing 20 mM Tris HCl, 150 mM NaCl,
and 1% NP-40. Protein phosphatase 1 (PP1) was immunoprecip-
itated from 600 mg of cellular protein using PP1 (FL-18) antibody.
Using P
32 labeled myelin basic protein as a substrate, the
phosphatase activity of the immunoprecipitated PP1 was mea-
sured with the aid of the protein serine/threonine phosphatase
(PSP) assay system. Labeling of the substrate and assay were
performed as per the manufacturer’s instructions.
Ethics Statement
Mice were housed and cared for in accordance with the
Institute of Laboratory Animal Research (ILAR) Commission on
Life Sciences, National Research Council document ‘‘Guide for
the care and use of laboratory animals’’. The animal study
protocol was reviewed by the Institutional Animal Care and use
Committee at the University of Texas Health Science Center at
San Antonio.
DMBA/Avicin treatment of mice
Skin carcinogenesis was induced using DMBA as described
earlier [9]. Seven-week old SENCAR mice from National Cancer
Institute (Fredrick, MD) were used for the study. 100 nmol of 7,
12-Dimethylbenz[a]anthracene (DMBA) in 0.2 ml acetone was
applied to the shaved dorsal areas of the mice, twice a week for 8
weeks. Avicin solutions (1 mg in 0.2 ml acetone) were applied to
the shaved area of the experimental animals 15 min before DMBA
application, twice a week for 8 weeks. Assessment of the
performance of animals and tumor progression has been described
earlier [9].
Immunohistochemistry
Skin sections prepared by standard procedures described earlier
[9], were incubated with primary antibodies against VEGF and
CD31. The murine skin sections were incubated overnight with
the primary antibody at 4uC followed by incubation with the
Avicin-D Inactivates Stat3
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Inc., Burlingame, CA, USA) for 2 h. Slides were then stained with
diaminobenzidine-chromogen and counterstained with aqueous
hematoxylin.
Statistical analysis
Each experiment or assay was performed at least three times in
triplicate and representative examples are shown. Data are
reported as means6SD. Statistical significance between and
treated samples was calculated using the Student’s t-test. P,0.05
were considered significant. For the animal studies, one-way
ANNOVA was performed on the measured parameters to
determine the significance of changes between the treated and
control groups. Again p,0.05 were considered significant.
Supporting Information
Figure S1 Chemical nature of avicins. (A) HPLC profile of
avicins. (B) Chemical structure of avicin D and avicin G.
Found at: doi:10.1371/journal.pone.0005578.s001 (0.30 MB TIF)
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